论文部分内容阅读
目的:探讨4例预后不良的t(8;21)急性髓细胞白血病临床和实验室特征。方法:用荧光原位杂交法(F ISH)检测AM L1/ETO融合基因,三色直接免疫荧光流式细胞仪检测白血病细胞表面抗原。结果:4例患者的AM L1/ETO融合基因均为阳性,白血病细胞免疫表型为CD 13、CD 33、CD 19阳性,CD 34、CD 56抗原高表达,2例正规化疗2个疗程无效,2例1个疗程达到完全缓解,但1例巩固治疗2个疗程后复发,1例大剂量阿糖胞苷巩固治疗3疗程停药4个月后复发。结论:预后不良的t(8;21)急性髓细胞白血病可能与附加染色体异常和CD 56抗原高表达有关。
Objective: To investigate the clinical and laboratory features of 4 patients with poor prognosis of t (8; 21) acute myeloid leukemia. Methods: AM L1 / ETO fusion gene was detected by fluorescence in situ hybridization (FISH), and the surface antigens of leukemia cells were detected by three-color direct immunofluorescence flow cytometry. Results: The AM L1 / ETO fusion gene was positive in all 4 patients. The immunophenotypes of leukemia cells were CD13, CD33 and CD19 positive, CD34 and CD56 antigens were highly expressed, and 2 cases of 2 chemotherapy regimens were ineffective. 2 cases of a course of treatment to achieve complete remission, but 1 case of consolidation treatment recurrence after 2 courses of treatment, 1 case of high dose of cytarabine consolidation therapy for 3 courses discontinued 4 months after the recurrence. CONCLUSION: T (8; 21) acute myeloid leukemia with poor prognosis may be associated with additional chromosomal abnormalities and high expression of CD56 antigen.